Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Key Terms

noninfectious conjunctival hyperemia medical

Redness of the white part of the eye caused by widened blood vessels that is not due to an infection. It’s like skin turning red from irritation or rubbing rather than from a cut or bug bite. For investors, it matters because this side effect can affect a drug or device’s safety profile, regulatory review, labeling, and patient acceptance, which in turn can influence market uptake and sales.

dry eye disease medical

Dry eye disease is a chronic condition where the eyes do not make enough tears or the tears evaporate too quickly, causing irritation, blurred vision and sensitivity to light — imagine having tiny grains of sand or a windshield with streaks that never clear. It matters to investors because it creates steady demand for prescription drugs, medical devices and diagnostic tests; treatments can be long‑term, subject to regulatory approval and insurance coverage, and successful products can capture large, recurring revenue streams.

tachyphylaxis medical

A rapid loss of a drug’s effectiveness after repeated or continuous use, where the body stops responding as strongly to the same dose. For investors, tachyphylaxis matters because it can shorten how long a treatment stays useful, force higher or more frequent dosing, complicate clinical trials and regulatory approval, and reduce long-term sales — similar to a product that quickly wears out and needs constant replacement or upgrades.

α2-adrenergic receptor (AR) agonist medical

An α2-adrenergic receptor (AR) agonist is a drug that acts like a key fitting specific proteins (α2 receptors) on nerve and blood vessel cells to dial down signals such as pain, stress-related neurotransmitter release, and sympathetic nervous system activity. Investors care because these drugs can treat conditions like high blood pressure, pain, or sleep disorders, so their effectiveness, safety profile, patent position, and regulatory pathway directly affect market potential and commercial risk.

venules medical

Venules are the small blood vessels that collect blood from the tiniest capillaries and carry it into larger veins, acting like neighborhood gutters that funnel fluid toward the main sewer. They matter to investors because many drugs, medical devices and imaging tests target or affect these vessels — changes in venule function can influence disease outcomes, safety profiles, regulatory review and market demand for related treatments.

arterioles medical

Arterioles are the smallest branches of the arterial system that connect larger arteries to the capillary networks and act like adjustable faucets that narrow or widen to control blood flow and pressure in specific tissues. They matter to investors because many drugs and medical devices aim to influence arteriole function to treat conditions such as high blood pressure and certain lung or heart diseases, and changes in this area can affect clinical outcomes, regulatory review, safety profiles, and market opportunity.

periocular region medical

The periocular region is the area immediately surrounding the eye, including the eyelids, the skin, and the tissues just beside the eye — think of it as the frame around a picture. For investors, it matters because treatments, devices, or cosmetic products aimed at this small but sensitive zone can have distinct safety, effectiveness, regulatory and market implications compared with therapies for other body parts, affecting trial design, approval risk and commercial demand.

over-the-counter (OTC) financial

Over-the-counter (OTC) describes stocks and other securities traded directly between buyers and sellers outside formal exchanges, using brokers, dealers, or electronic networks. For investors it matters because OTC trading often means lower transparency, fewer rules and thinner trading volume—like buying at a small flea market instead of a big supermarket—so prices can swing more and the risk of not being able to sell quickly is higher.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Global review highlights increasing prevalence of noninfectious ocular redness due to digital eye strain, dry eye disease, allergies and environmental exposures
• LUMIFY redness reliever eye drops (brimonidine tartrate 0.025%) are highlighted as a differentiated OTC option due to its highly selective α2 mechanism, with no tachyphylaxis over 29 days and virtually no rebound redness
• Review also notes a preservative-free formulation of brimonidine tartrate 0.025% showing comparable efficacy, safety and tolerability; Bausch + Lomb introduced LUMIFY Preservative Free Eye Drops in 2025

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative review examining the causes, burden and management of noninfectious conjunctival hyperemia (ocular redness). The review highlights the growing global prevalence of ocular redness driven by digital lifestyles, dry eye, contact lens wear, allergies and environmental factors, reinforcing how ocular redness affects both comfort and appearance.¹

Developed by clinical experts from nine countries, the publication underscores the aesthetic and psychosocial impact of ocular redness, noting that individuals with red eyes may be perceived as less healthy or more fatigued – a concern amplified by video conferencing and social media, which spotlight facial features, including the eyes and the periocular region. The authors also note that ocular redness frequently presents symptoms such as irritation, dryness, itching or foreign-body sensation, contributing to patient discomfort and reduced quality of life.

“Ocular redness is no longer just a clinical concern, it’s a global lifestyle and quality-of-life issue,” said Melissa Toyos, MD, lead author of the review and partner, Toyos Clinic, Nashville, Tenn. “Patients today are seeking effective, safe and aesthetically minded products, which makes understanding the differences in products more important than ever.”

Key clinical insights from the paper:

• Rising prevalence: Noninfectious conjunctival hyperemia is rising worldwide due to digital eye strain, dry eye disease, allergies, contact lens wear and environmental factors
• Limitations of traditional decongestants: Traditional α1 and mixed α1/α2 decongestants may provide short-term symptom relief but are prone to tachyphylaxis, rebound redness and shorter duration of effect
• Impact on comfort and appearance: Ocular redness is often accompanied by symptoms such as irritation and dryness, and may adversely affect quality of life due to both discomfort and aesthetic concerns
• Evidence for brimonidine tartrate 0.025%: Brimonidine tartrate 0.025% (LUMIFY Redness Reliever eye drops), a highly selective α2-adrenergic receptor (AR) agonist, demonstrated effective redness reduction with no tachyphylaxis over 29 days and virtually no rebound redness after discontinuation
• Aesthetic-driven OTC use: Patients increasingly seek safe OTC redness-relief products for aesthetic reasons, highlighting the importance of selective mechanisms and favorable safety profiles
• Need for patient education: Global gaps exist in patient awareness and clinical guidance, underscoring the importance of patient education, appropriate OTC product selection and awareness of safety considerations, especially amid increasing global self-treatment and concerns with unsafe or unapproved copycat or counterfeit redness relievers

“This publication reinforces the unique, mechanism-based advantages of LUMIFY,” said Mayssa Attar, senior vice president, Pharmaceuticals and Consumer R&D, Bausch + Lomb. “The evidence supporting selective α2-AR agonist mechanism clearly differentiates LUMIFY’s established safety and efficacy profile and reflects our commitment to delivering trusted, science-backed products for consumers.”

LUMIFY, formulated with low-dose brimonidine tartrate 0.025%, provides fast, effective redness reduction while avoiding tachyphylaxis and rebound redness associated with traditional decongestants. Its highly selective α2-AR agonist mechanism primarily constricts venules rather than arterioles, contributing to a favorable safety profile, tolerability and efficacy. Clinical evidence across four trials demonstrated no tachyphylaxis over 29 days and virtually no rebound redness upon discontinuation.

The review also notes a preservative-free formulation of brimonidine tartrate 0.025%, which demonstrated efficacy, safety and tolerability comparable to the original version with virtually no rebound redness. In 2025, Bausch + Lomb introduced LUMIFY Preservative Free Eye Drops in convenient single-use vials, offering patients an additional brimonidine-based option without preservatives.

For more information on LUMIFY and LUMIFY Preservative Free, visit www.lumifyeyes.com.

About Ocular Redness
Ocular redness, or conjunctival hyperemia, is a common condition that occurs when tiny blood vessels on the surface of the eye become enlarged or irritated, causing the eye to appear red or bloodshot. It can be caused by factors such as digital eye strain, dry eye disease, allergies, contact lens wear and environmental irritants. Mild redness can be accompanied by irritation or dryness and can impact comfort, appearance and confidence, prompting many people to seek over-the-counter relief.²

About LUMIFY Redness Reliever Eye Drops
LUMIFY is a redness reliever like no other. With its novel mechanism of action and favorable safety profile, LUMIFY has redefined the category and become an eye care staple – helping eyes look whiter, brighter and more beautiful. It’s the No. 1 eye doctor-recommended redness reliever eye drop brand and holds more than 60% market share. LUMIFY works in one minute and lasts up to eight hours when used as directed. In 2025, Bausch + Lomb introduced LUMIFY Preservative Free Eye Drops in convenient, single-use vials. For more information, visit www.lumifyeyes.com.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

References

1. Toyos M, Chan CC, Alio JL, Chong KKL, Pek D, Doan S, Sinjab M, Hosny M, Messmer EM, Giannaccare G. “Global Perspectives on Therapy for Noninfectious Conjunctival Hyperemia: A Narrative Review.” Ophthalmology and Therapy. 2026. https://doi.org/10.1007/s40123-026-01310-7.
2. Cleveland Clinic. Red Eye: Causes, Treatment & Prevention. 2023. https://my.clevelandclinic.org/health/symptoms/17690-red-eye.

©2026 Bausch + Lomb.
LUM.0051.USA.26

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224794302/en/

Media Contact:
Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

Source: Bausch + Lomb Corporation